Company profile
Royalty Pharma plc
NASDAQ: RPRX · Healthcare · Medical - Pharmaceuticals
#103 of 1,418 Healthcare companies by revenue49th-percentile growth
EA Score
72BFH 84DQ 62GM 63SS 63
v0.1 · 65/100 weight · provisional
↑ operating margin, market scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$2.4B
Rev growth YoY (TTM)
+7.8%
Net income (FY)
$770.9M
Employees
100
as of 2026-08-05
Market cap
$24.7B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.4B$2.4B2025
Net income$770.9M$770.9M2025
Operating income$1.6B$1.6B2025
Total assets$19.6B$19.6B2025
Liabilities$9.9B$9.9B2025
Equity$9.7B$9.7B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Financial Royalty Assets95%
Royalty Income, Other5%
By geography
Not disclosed.
The read
What is Royalty Pharma plc’s revenue?
Royalty Pharma plc booked $2.4B in FY2025 revenue, growing 5.1% year over year — about the middle of the pack among Healthcare companies we track, at a 32.4% net margin.
Peers · Healthcare
Chemed Corporation89ATeladoc Health, Inc.70BAveanna Healthcare Holdings Inc.66BHims & Hers Health, Inc.68BExelixis, Inc.89ANatera, Inc.75B+Neighbors
New York →Key facts
CEOPablo Legorreta
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersNew York, NY
ExchangeNASDAQ: RPRX
Employees100
IPO date2020-06-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.